Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169) | Zendy

Andréanne Lupien | Zendy; Anthony Vocat | Zendy; Caroline S. Foo | Zendy; Emilyne Blattes | Zendy; JeanYves Gillon | Zendy; Vadim Makarov | Zendy; Stewart T. Cole | Zendy

Open Access

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)

Author(s) -

Andréanne Lupien,

Anthony Vocat,

Caroline S. Foo,

Emilyne Blattes,

JeanYves Gillon,

Vadim Makarov,

Stewart T. Cole

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00840-18

Subject(s) - ethambutol , pyrazinamide , medicine , regimen , tuberculosis , mycobacterium tuberculosis , isoniazid , extensively drug resistant tuberculosis , antibiotics , drug , pharmacology , drug resistance , clinical trial , rifapentine , intensive care medicine , microbiology and biotechnology , biology , latent tuberculosis , pathology

The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin, pyrazinamide, and ethambutol) for the treatment of tuberculosis (TB) is menaced by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains ofMycobacterium tuberculosis . Intensive efforts have been made to develop new antibiotics or to repurpose old drugs, and several of these are currently being evaluated in clinical trials for their antitubercular activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research